Miacalcic (Calcitonin)

Calcitonin binds to calcitonin receptors on osteoclasts, the cells responsible for breaking down bone. This binding inhibits osteoclast activity, decreasing bone resorption and the release of calcium into the bloodstream. The hormone also promotes renal excretion of calcium, contributing to lower serum calcium concentrations.

The dosage of Miacalcic is individualized by the prescribing clinician based on the specific indication, patient characteristics, and clinical response. Healthcare professionals determine the appropriate strength, frequency, and route of administration, and patients should follow the prescriber’s instructions without deviation.

Safety data for calcitonin in pregnancy and lactation are limited. The product should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians typically weigh the benefits against uncertainties and may consider alternative therapies when possible.

To request Miacalcic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

The primary alternative for managing bone loss and hypercalcemia is the bisphosphonate class. Bisphosphonates also inhibit osteoclast‑mediated bone resorption but have a different mechanism and longer skeletal retention. Calcitonin offers a rapid, short‑acting effect and can be useful when bisphosphonates are contraindicated or not tolerated.

Miacalcic must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, discard the product to ensure safety and efficacy.

Miacalcic is supplied as an injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site is typically the thigh, upper arm, or abdomen, depending on the chosen route and patient factors.

Serious adverse events include severe allergic reactions such as anaphylaxis, marked hypotension, clinically significant hypocalcemia, and, rarely, osteosarcoma with long‑term use. Patients should be instructed to seek immediate medical attention if they experience difficulty breathing, swelling, faintness, or persistent low calcium symptoms.

Miacalcic is contraindicated in individuals with known hypersensitivity to calcitonin or any excipients in the formulation. Caution is advised for patients with severe renal impairment, uncontrolled hypocalcemia, or a history of osteosarcoma. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.